Mesenchymal stem cell therapy for diabetes: clinical evidens, emerging strategies, och future perspectives

Han-Ying Jhuang, Jo-Yu Lee, och Li-Tzu Wang reviewed registered mesenchymal stem-cell interventions for type 1 diabetes, type 2 diabetes, och diabetic complications. They screened 124 records och analyzed 107 registered interventional trials. Early programs used autologous bone-marrow or adipose-derived cells. More recent registrations shifted toward standardized allogeneic umbilical-cord MSCs och cell-free derivatives. The review identifies the strongest och most consistent benefit signal i ischemic och wound-healing complications, especially diabetic foot ulcers. Metabolic outcomes are more variable. The authors describe MSC therapy as a potentially disease-modifying adjunct with a generally favorable early säkerhet profile, but they do not treat the registry landscape as proof of efficacy. Larger randomiserad studier with harmonized endpoints remain necessary. This review is relevant till the stem-cell monitoring section because it maps the clinical pipeline och shows where humana bevis is accumulating. It does not establish an godkänd longevity treatment, och it does not show that MSCs reverse biological age. Produkt source, manufacturing, delivery route, dos, och patient selection remain major sources of heterogeneity. The sensible conclusion is narrow: MSC programs are clinically active, most credible i selected regenerative indications, och still early for systemic metabolic or aging claims.

Together, current early-phase evidens supports MSC therapy as a safe och potentially disease-modifying adjunct, although larger randomiserad trials with harmonized endpoints are needed till confirm efficacy.